Evidence map›Paper›PMID 21410454›Full record

ReviewBritish journal of pharmacology2011

Predictive animal models of mania: hits, misses and future directions.

Jared W Young, Brook L Henry, Mark A Geyer

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 129 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jared W YoungDepartment of Psychiatry, University of California San Diego, La Jolla, CA 92093-0804, USA. jaredyoung@ucsd.edu
Brook L Henry
Mark A Geyer
University of California, San Diego · US

Funding

Inhibitory Deficits in Mania and Hyperdopaminiergic MiceR01MH071916 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A, PERRY, WILLIAM · 2004 to 2014
$4.2M
MONOAMINES &HALLUCINOGENS'EFFECTS ON RAT BEHAVIORR01DA002925 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A · 1985 to 2015
$4.2M
The rodent continuous performance task: Filling the vigilance translational gapR21MH085221 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YOUNG, JARED WILLIAM · 2009 to 2010
$418k
Inhibitory Deficits in Bipolar Disorder and Methamphetamine DependenceF32DA024524 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HENRY, BROOK · 2009 to 2010
$102k
NIDA NIH HHS F32 DA024524NIDA NIH HHS F32-DA024524NIDA NIH HHS R01 DA002925NIDA NIH HHS R01-DA002925NIMH NIH HHS R01 MH071916NIMH NIH HHS R01-MH071916NIMH NIH HHS R21 MH085221NIMH NIH HHS R21-MH085221
6 · The paper itself

Abstract

Mania has long been recognized as aberrant behaviour indicative of mental illness. Manic states include a variety of complex and multifaceted symptoms that challenge clear clinical distinctions. Symptoms include over-activity, hypersexuality, irritability and reduced need for sleep, with cognitive deficits recently linked to functional outcome. Current treatments have arisen through serendipity or from other disorders. Hence, treatments are not efficacious for all patients, and there is an urgent need to develop targeted therapeutics. Part of the drug discovery process is the assessment of therapeutics in animal models. Here we review pharmacological, environmental and genetic manipulations developed to test the efficacy of therapeutics in animal models of mania. The merits of these models are discussed in terms of the manipulation used and the facet of mania measured. Moreover, the predictive validity of these models is discussed in the context of differentiating drugs that succeed or fail to meet criteria as approved mania treatments. The multifaceted symptomatology of mania has not been reflected in the majority of animal models, where locomotor activity remains the primary measure. This approach has resulted in numerous false positives for putative treatments. Recent work highlights the need to utilize multivariate strategies to enable comprehensive assessment of affective and cognitive dysfunction. Advances in therapeutic treatment may depend on novel models developed with an integrated approach that includes: (i) a comprehensive battery of tests for different aspects of mania, (ii) utilization of genetic information to establish aetiological validity and (iii) objective quantification of patient behaviour with translational cross-species paradigms.

Indexed as

Disease Models, AnimalAnimalsAntipsychotic AgentsBipolar DisorderForecastingHumansMaleMiceModels, GeneticPsychiatric Status Rating ScalesRatsReproducibility of ResultsAntipsychotic Agents

Identifiers

PMID21410454
PMCPMC3229761
OpenAlexW1574195882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.